Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars

Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars·Investor's Business Daily
In this article:

Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket.

Advertisement